Skip to main content

Table 2 Performance of candidate TMs and post-NACT CTM for predicting risk of 3-year PFS

From: Combination of tumor markers predicts progression and pathological response in patients with locally advanced gastric cancer after neoadjuvant chemotherapy treatment

 

AUC (95% CI)

P

P (compare to CTM)

CEA

0.592 (0.552–0.658)

0.001

0.003

CA19-9

0.620 (0.569–0.673)

 < 0.001

0.011

CA72-4

0.597 (0.542–0.646)

 < 0.001

 < 0.001

Post-NACT CTM

0.681 (0.635–0.727)

 < 0.001

1.000

  1. CI, confidence interval; AUC, area under curve; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; CA72-4, carbohydrate antigen 72-4; CEA, carcinoembryonic antigen; CI, confidence interval; CTM, combination of tumor markers; Calculation of confidence interval and P value are based on Inverse Probability of Censoring Weighting method
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us